Experience with anti-TNF-α therapy for orofacial granulomatosis

Journal of Oral Pathology and Medicine

Volumn 40, Issue 1, 2011, Pages 14-19

  Elliott, Tim ^a   Campbell, Helen ^a   Escudier, Michael ^a   Poate, Tim ^a   Nunes, Carlo ^a   Lomer, Miranda ^a   Mentzer, Alex ^a   Patel, Pritash ^a   Shirlaw, Penelope ^a   Brostoff, Jonathon ^a   Challacombe, Stephen ^a   Sanderson, Jeremy ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Adalimumab; Anti TNF ; Crohn's disease; Infliximab; Orofacial granulomatosis

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BENZOIC ACID; BETAMETHASONE SODIUM PHOSPHATE; C REACTIVE PROTEIN; FUSIDATE SODIUM; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; STEROID; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANAPHYLACTOID PURPURA; ARTICLE; CINNAMON; CLINICAL ARTICLE; CROHN DISEASE; DIET RESTRICTION; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EAR INFECTION; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; KAPLAN MEIER METHOD; LIP RECONSTRUCTION; MOUTH DISEASE; OROFACIAL GRANULOMATOSIS; PREDICTION; PRIORITY JOURNAL; REPEATED DRUG DOSE; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; FEMALE; GRANULOMATOSIS, OROFACIAL; HUMANS; MALE; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650787708     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00976.x     Document Type: Article

References (26)

1. Wiesenfeld D, Ferguson MM, Mitchell DN, et al. Orofacial granulomatosis - a clinical and pathological analysis. Q J Med 1985; 54: 101-13.
2. Taibjee SM, Prais L, Foulds IS. Orofacial granulomatosis worsened by chocolate: results of patch testing to ingredients of Cadbury's chocolate. Br J Dermatol 2004; 150: 595.
3. Guttman-Yassky E, Weltfriend S, Bergman R. Resolution of orofacial granulomatosis with amalgam removal. J Eur Acad Dermatol Venereol 2003; 17: 344-7.
4. Tilakaratne WM, Freysdottir J, Fortune F. Orofacial granulomatosis: review on aetiology and pathogenesis. J Oral Pathol Med 2008; 37: 191-5.
5. James DG. Differential diagnosis of facial nerve palsy. Sarcoidosis Vasc Diffuse Lung Dis. 1997; 14: 115-20.
6. Rosenthal C. Fazialislahmung, angineurotschem Gesichtsodem und Lingua plicata in Arthrismusfamilien. Ztschr Neurol Psych 1932; 131: 475.
7. Rowland M, Fleming P, Bourke B. Looking in the mouth for Crohn's disease. Inflamm Bowel Dis 2010; 16: 332-7.
8. White A, Nunes C, Escudier M, et al. Improvement in orofacial granulomatosis on a cinnamon and benzoate-free diet. Inflamm Bowel Dis 2006; 12: 508-14.
9. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47: 436-40.
10. Allen CM, Camisa C, Hamzeh S, Stephens L. Cheilitis granulomatosa: report of six cases and review of the literature. J Am Acad Dermatol 1990; 23: 444-50.
11. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 21: CD000067.
12. Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; 16: CD000545.
13. Mentzer AJ, Campbell H, Elliott T, Escudier M, Challacombe S, Sanderson J. The varied response of orofacial granulomatosis to azathioprine. Gut 2010; 59(Suppl III): A302.
14. Freysdottir J, Zhang S, Tilakaratne WM, Fortune F. Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment. Inflamm Bowel Dis 2007; 13: 439-45.
15. Peitsch WK, Kemmler N, Goerdt S, Goebeler M. Infliximab: a novel treatment option for refractory orofacial granulomatosis. Acta Derm Venereol 2007; 87: 265-6.
16. Gaya DR, Aitken S, Fennell J, Satsangi J, Shand AG. Anti-TNF-α-alpha therapy for orofacial granulomatosis: proceed with caution. Gut 2006; 55: 1524-5.
17. Ratzinger G, Sepp N, Vogetseder W, Tilg H. Cheilitis granulomatosa and Melkersson-Rosenthal syndrome: evaluation of gastrointestinal involvement and therapeutic regimens in a series of 14 patients. J Eur Acad Dermatol Venereol 2007; 21: 1065-70.
18. Barry O, Barry J, Langan S, et al. Treatment of granulomatous cheilitis with infliximab. Arch Dermatol 2005; 141: 1080-2.
19. Quezeda S, Tumer PL, Alexiev B, Daly B, Cross R. Severe refractory orofacial Crohn's disease: report of a case. Dig Dis Sci 2009; 54: 2290-5.
20. Kakimoto C, Sparks C, White AA. Melkersson-Rosenthal syndrome: a form of pseudoangioedema. Ann Allergy Asthma Immunol 2007; 99: 185-9.
21. Groselj D, Grabec I, Seme K, Lhan A, Ferkolj I. Prediction of clinical response to anti-TNF-α treatment by oral parameters in Crohn's disease. Hepatogastroenterology 2008; 55: 112-9.
22. Cardoso H, Nunes AC, Carneiro F, Tavarela Veloso F. Successful infliximab therapy for oral Crohn's disease. Inflamm Bowel Dis 2006; 12: 337-8.
23. Mahadevan U, Sandborn WJ. Successful infliximab therapy for oral Crohn's disease. Inflamm Bowel Dis 2006; 12: 337-8.
24. Campbell H, Patel P, Nunes C, et al. A clinical overview of the presentation and management of orofacial granulomatosis in a combined oral medicine and gastroenterology clinic. Gut 2010; 1: A39-40, Abstract.
25. Hegarty A, Hodgson T, Porter S. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 576-85.
26. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990; 126: 923-7.